A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : FIB-4 / fibrosis-4 index

[Related PubMed/MEDLINE]
Total Number of Papers: 74
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   FIB-4  (>> Co-occurring Abbreviation)
Long Form:   fibrosis-4 index
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Association of grip strength with non-alcoholic fatty liver disease: investigation of the roles of insulin resistance and inflammation as mediators. CRP, NAFLD, TyG
2020 Associations of Liver Disease with Alcohol Use among People Living with HIV and the Role of Hepatitis C: The New Orleans Alcohol Use in HIV Study. APRI, AST, HCV, LDH, NOAH, PLWH
2020 Changing Patterns of Hepatocellular Carcinoma after Treatment with Direct Antiviral Agents. AFP, DAAs, HCC, MELD, PVT
2020 Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease. NAFLD
2020 Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C. AUC
2020 Diagnostic performance of Mac-2 binding protein glycosylation isomer (M2BPGi) in screening liver fibrosis in health checkups. APRI, COI, M2BPGi, MRE
2020 Effect of Non-alcoholic Fatty Liver Disease on the Risk of Synchronous Liver Metastasis: Analysis of 451 Consecutive Patients of Newly Diagnosed Colorectal Cancer. CRC, NAFLD, NFS, synCRLM
2020 Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. CI, T2DM
2020 Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. ALT, AST, GGT, LDL-C, LFC, NAFLD, SAT, T2DM, VAT
10  2020 Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co-infected Adults. HBV, VCTE
11  2020 Fibrosis-4 index at diagnosis can predict all-cause mortality in patients with rheumatoid arthritis: A retrospective monocentric study. CRP, DM, ESR, HTN, RA
12  2020 Hepatic Fibrosis Assessed Using Fibrosis-4 Index Is Predictive of All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease. COPD, HR
13  2020 Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents. CI, OR, SUA
14  2020 Liver fibrosis with two-dimensional shear-wave elastography in patients with autoimmune hepatitis. AIH, APRI, AUROCs
15  2020 Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis. CIs, HRs, HS
16  2020 Lymphocyte-To-Monocyte Ratio as the Best Simple Predictor of Bacterial Infection in Patients with Liver Cirrhosis. AAR, APRI, AST, AUC, CRP, CTP, LMR, MELD, NLR, NMR, OR, PLR, SBP, UTI
17  2020 Portal Venous Pulsatility Index: A Novel Biomarker for Diagnosis of High-Risk Nonalcoholic Fatty Liver Disease. APRI, AST, FS, NAFLD, VPI
18  2020 Predictive score for hepatocellular carcinoma after hepatitis B eantigen loss in patients treated with entecavir or tenofovir. AUC, AVT, CHB, CI, ESC, ETV, HCC, HR, TDF
19  2020 Prospective comparison of transient elastography, point shear wave elastography, APRI and FIB-4 for staging liver fibrosis in chronic viral hepatitis. APRI, AUROC, SWE, TE
20  2020 Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. aHR, HRs
21  2020 Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus. BMI, CI, LSMI, OR, T2DM
22  2020 Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. NAFLD, NFS, NPVs
23  2020 The FIB-4 Index Is Associated with Need for Mechanical Ventilation and 30-day Mortality in Patients Admitted with COVID-19. ---
24  2020 The prognostic value and non-invasive predictors of splenomegaly in cirrhotic patients with hepatocellular carcinoma following curative resection. AAR, API, AST, HCC, ROC, TNM, USG
25  2020 The sex-specific effects of blood lead, mercury, and cadmium levels on hepatic steatosis and fibrosis: Korean nationwide cross-sectional study. HS, HSI, NAFLD
26  2020 The utility of two-dimensional real-time shear wave elastography for assessing liver fibrosis in patients with chronic hepatitis C virus infection. AUROCs, M2BPGi, MRE, PLT
27  2020 [Diagnostic value of liver stiffness measurement for the evaluation of liver fibrosis in nonalcoholic fatty liver]. APRI, LSM, NAFLD, NFS, ROC
28  2019 Acoustic radiation force impulse elastography of liver as a screening tool for liver fibrosis in alcoholic liver disease. APRI, ARFI, AUROC
29  2019 ALBI/ST ratio versus FIB-4 and APRI as a predictor of posthepatectomy liver failure in hepatocellular carcinoma patients. ARPI, HCC, PHLF
30  2019 Aspartate Aminotransferase-to-Platelet Ratio or Fibros-4 Index Predicts the Development of Hepatocellular Carcinoma in Chronic Hepatitis C Patients with Sustained Virologic Response to Interferon Therapy. APRI, CHC, HCC, SVR
31  2019 Aspartate transaminase to platelet ratio index (APRI) but not FIB-5 or FIB-4 is accurate in ruling out significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) in an urban slum-dwelling population. APRI, AST, NAFLD, SF
32  2019 Association between Liver Fibrosis and Serum PSA among U.S. Men: National Health and Nutrition Examination Survey (NHANES), 2001-2010. aOR, APRI, CI, NFS, NHANES
33  2019 Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial. APRI, ART, CI, HIV, HR, START
34  2019 Comparison of non-invasive liver reserve and fibrosis models: Implications for surgery and prognosis for hepatocellular carcinoma. APRI, AUC, HCC, MST, OS, PALBI, RFS
35  2019 Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C. AUC
36  2019 Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease. AUROC, ELF, LSM, NAFLD, NASH, NFS, ROC
37  2019 External validation of Liaoning score for predicting esophageal varices in liver cirrhosis: a Chinese multicenter cross-sectional study. AAR, AST, AUCs, EVs, GIB
38  2019 Fibrosis-4 index at diagnosis is associated with all-cause mortality in patients with microscopic polyangiitis and granulomatosis with polyangiitis. BVAS, DM, GPA, HR, HTN, MPA
39  2019 Fibrosis-4 index predicts mortality in HIV/HCV co-infected patients receiving combination antiretroviral therapy in rural China. cART, ESLD, HRs, PY
40  2019 FICK-3 Score Combining Fibrosis-4, Insulin Resistance and Cytokeratin-18 in Predicting Non-alcoholic Steatohepatitis in NAFLD Egyptian Patients. AUC, CK18-Fs, HOMA-IR, ROC
41  2019 High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naive and experienced chronic hepatitis C genotype 4: Real world results. AEs, EOT, HCV, SOF
42  2019 Impact of Implementing a "FIB-4 First" Strategy on a Pathway for Patients With NAFLD Referred From Primary Care. NAFLD, VCTE
43  2019 Insulin Resistance Associated Disorders Pivoting Long-Term Hepatitis B Surface Antigen Decline During Entecavir Therapy. CHB, HBsAg, IRAD, T2DM
44  2019 Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study. CIs, HRs, NAFLD, NFS
45  2019 Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort. APRI, AUROC, ELF, HA, NAFLD, NPV, PIIINP, PPV, TIMP
46  2019 Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis. AF, AIH, APRI, AUROC, CI, DOR, MRE, ROC, SF, TE
47  2019 The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals. CAP, CHC, DAAs, LS, SVR12
48  2019 The combination of the preoperative albumin-bilirubin grade and the fibrosis-4 index predicts the prognosis of patients with hepatocellular carcinoma after liver resection. ALBI, ALBI-FIB-4, HCC, OS, RFS
49  2018 Acoustic Radiation Force Impulse US Imaging: Liver Stiffness in Patients with Chronic Hepatitis B with and without Antiviral Therapy. ARFI, US
50  2018 APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level. AST, AUROC, CHC
51  2018 Assessment of liver fibrosis in Egyptian chronic hepatitis B patients: A comparative study including 5 noninvasive indexes. AAR, APRI, AUROC, CHB, RPR
52  2018 Evaluating Diagnostic Accuracy of Noninvasive Tests in Assessment of Significant Liver Fibrosis in Chronic Hepatitis C Egyptian Patients. AAR, AP index, APRI, AUROC, CDS, CHC, FibroQ, GUCI, NPV, PPV, TE
53  2018 FIB-4 and APRI scores for predicting severe fibrosis in chronic hepatitis C - a developing country's perspective in DAA era. APRI, HCV
54  2018 Fibrosis-4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection. HBV
55  2018 Liver Fibrosis with Two-dimensional US Shear-Wave Elastography in Participants with Chronic Hepatitis B: A Prospective Multicenter Study. APRI, CI, SWE, TE
56  2018 Missed Diagnosis of Liver Cirrhosis Leads to Disparities in Care for Older Patients. AST, HCC, MELD
57  2018 Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection. AFP, GT, HCV
58  2018 Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease. AAR, APRI, ARFI, AUROC, LSMs, NAFLD, NFS
59  2018 Validation of modified fibrosis-4 index for predicting hepatocellular carcinoma in patients with compensated alcoholic liver cirrhosis. ALC, APRI, AUROC, eLIFT, HCC, mFIB-4
60  2017 Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. AF, APRI, AUROC, LF, MRE, NAFLD, NFS, SF, SWE
61  2017 Diminished accuracy of biomarkers of fibrosis in low replicative chronic hepatitis B. API, AST, AUROC, HBV
62  2017 FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients. CHF, HCV, HIV
63  2017 Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement. ALT, APRI, AST, DAA, HCV, LSM, SVR-24
64  2017 Noninvasive Assessment of Liver Fibrosis Stage Using Ultrasound-Based Shear Wave Velocity Measurements and Serum Algorithms in Patients With Viral Hepatitis B: A Retrospective Cohort Study. AAR, APRI, AUC, SWV
65  2017 Novel serum biomarkers modified by the body mass index z-score for the detection of liver fibrosis and steatosis in children with chronic hepatitis C. AST, AUROC, BMI z-score, CHC, M-APRI
66  2017 Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data. APRI, AST, NAFL, NAFLD, NASH, NFS, NHANES
67  2017 Quantitative Measurement of Hepatic Fibrosis with Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Patients with Chronic Hepatitis B Infection: A Comparative Study on Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis-4 Index. APRI, CHB, CV, MR, ROC
68  2017 SVR Rates of HCV-infected population under PEG-IFN-alpha/R treatment in Northwest China. APRI, SNP, SVR
69  2016 Chemerin, retinol binding protein-4, cytokeratin-18 and transgelin-2 presence in sera of patients with non-alcoholic liver fatty disease. CK-18, MS, RBP4
70  2016 Chemerin, retinol binding protein-4, cytokeratin-18 and transgelin-2 presence in sera of patients with non-alcoholic liver fatty disease. CK-18, MS, RBP4
71  2016 Diagnostic Performance of Real-Time Elastography in the Assessment of Advanced Fibrosis in Chronic Hepatitis C. APRI, AST, AST, AUROC, CHC, LB, LFI, NPV, RTE
72  2016 Early non-invasive selection of patients at high risk of severe hepatitis C recurrence after liver transplantation. APRI, ELF, HCV, IFN, IP-10
73  2016 Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study. cART, gamma-GT, HCV, HIV, LF, NRTI, PYFU
74  2016 LOGIQ E9 Shear Wave Elastrography for Detection of Liver Fibrosis in Patients with Chronic Hepatitis C Virus. APRI, GE, NPV, PPV, SWE